Novo Nordisk: Aggressive Dip-Buying Opportunity Has Finally Arrived
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Zacks.com on MSN4h
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...
FDA says the Zepbound shortage is over. Here's what that means for compounding pharmacies, patients who used off-brand versions
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
FDA approves Hikma’s generic version of Novo’s diabetes drug Victoza
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...
WAAY-TV21h
There’s still no generic Ozempic, but a lower-priced daily injected GLP-1 is coming
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
7 types of foods and drinks to avoid when taking Ozempic or Wegovy for weight loss
Weight loss with Ozempic or Wegovy can come with nausea, but avoiding certain foods and drinks can help patients manage the ...
KOMU23h
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
The study met its main goal, but those watching closely had hoped for an average result of at least 25% weight loss.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
STAT1d
Vertex drug for cystic fibrosis wins approval
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Why are people microdosing Ozempic?
Tiny doses of the weight-loss drug can sidestep its unpleasant side effects, say influencers. But is customising the dose a ...
Novo Nordisk's 27% drop was market overreaction, analysts say
Novo Nordisk's shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...
Novo Nordisk price target lowered to DKK 900 from DKK 1,050 at Barclays
Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 900 from DKK 1,050 and keeps an Overweight rating on the shares. The firm ...